Evidence map›Paper›PMID 22120109›Full record

ArticleBiochimie2012

The receptor binding domain of botulinum neurotoxin serotype C binds phosphoinositides.

Yanfeng Zhang, Susan M Varnum

Abstract read
In one paragraph

Article in Biochimie, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Botulinum Neurotoxins: Mechanism of Action.Handbook of experimental pharmacology · 2021
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yanfeng ZhangCell Biology and Biochemistry Group, Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99352, USA.
Susan M Varnum
Pacific Northwest National Laboratory · US

Funding

Detection of Toxins: A Combined ELISA Microarray and Activity Assay PlatformU01AI081895 · NIAID · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI VARNUM, SUSAN · 2009 to 2013
$2.6M
NIAID NIH HHS U01 AI081895NIAID NIH HHS U01AI081895
6 · The paper itself

Abstract

Botulinum neurotoxins (BoNTs) are the most toxic proteins known for humans and animals with an extremely low LD(50) of ∼1 ng/kg. BoNTs generally require a protein and a ganglioside on the cell membrane surface for binding, which is known as a "dual receptor" mechanism for host intoxication. Recent studies have suggested that in addition to gangliosides, other membrane lipids such as phosphoinositides may be involved in the interactions with the receptor binding domain (HCR) of BoNTs for better membrane penetration. Using two independent lipid-binding assays, we tested the interactions of BoNT/C-HCR with lipids in vitro domain. BoNT/C-HCR was found to bind negatively charged phospholipids, preferentially phosphoinositides in both assays. Interactions with phosphoinositides may facilitate tighter binding between neuronal membranes and BoNT/C.

Indexed as

Botulinum ToxinsLiposomesPhosphatidylinositolsProtein BindingBotulinum Toxinsbotulinum toxin type CLiposomesPhosphatidylinositols

Identifiers

PMID22120109
PMCPMC3277684
OpenAlexW2054998947

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.